



SDI Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_45709
Title of the Manuscript:	A review on fumonisins
Type of the Article	Review Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	Nil	
Minor REVISION comments	Nil	
Optional/General comments	Well, the review article is better written. It can be accepted in the present format for publication in the journal. Some references may be included containing latest research relevant to the review article.	Recently investigation about fumonisins was limited, but yet exist concerning about the toxic effects of fumonisins in the world (especially in Iran). So it was necessary to remember fumonisins using a review manuscript to refresh this mycotoxin subject. Also, we tried to use the accessible and newest researches for the manuscript.

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	No, there are not any ethical issues in this manuscript.